Cyclacel Pharmaceuticals (NASDAQ:CYCC) Upgraded at Wall Street Zen

Cyclacel Pharmaceuticals (NASDAQ:CYCC) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Cyclacel Pharmaceuticals Trading Down 10.6%

Shares of CYCC stock opened at $7.95 on Friday. The firm has a 50-day moving average price of $7.54 and a 200 day moving average price of $42.57. Cyclacel Pharmaceuticals has a twelve month low of $3.08 and a twelve month high of $597.60. The company has a market capitalization of $12.56 million, a price-to-earnings ratio of -0.01 and a beta of 0.08.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its earnings results on Wednesday, August 13th. The biotechnology company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($72.00) by $71.02.

Insider Buying and Selling

In other Cyclacel Pharmaceuticals news, major shareholder David E. Lazar sold 6,750 shares of Cyclacel Pharmaceuticals stock in a transaction dated Wednesday, July 30th. The stock was sold at an average price of $12.36, for a total value of $83,430.00. Following the completion of the sale, the insider owned 155,838 shares in the company, valued at $1,926,157.68. The trade was a 4.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 51.20% of the stock is owned by company insiders.

Institutional Trading of Cyclacel Pharmaceuticals

An institutional investor recently raised its position in Cyclacel Pharmaceuticals stock. Armistice Capital LLC raised its holdings in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) by 118.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,269,485 shares of the biotechnology company’s stock after buying an additional 689,024 shares during the quarter. Armistice Capital LLC owned approximately 0.61% of Cyclacel Pharmaceuticals worth $354,000 at the end of the most recent quarter. Institutional investors and hedge funds own 23.58% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.